Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies

Clinics in Dermatology

Volumn 28, Issue 1, 2010, Pages 67-72

  Naldi, Luigi ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PSORALEN;

ARTICLE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; HUMAN; INTERRATER RELIABILITY; INTRARATER RELIABILITY; LIFE STRESS; LONG TERM CARE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; PUVA; QUALITY OF LIFE; RELIABILITY; REPRODUCIBILITY; SCORING SYSTEM; STANDARDIZATION;

DERMATOLOGIC AGENTS; DERMATOLOGY; HUMANS; MODELS, STATISTICAL; MODELS, THEORETICAL; PSORIASIS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 71749085643     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.03.001     Document Type: Article

References (34)

1. Jobling R., and Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 126 (2006) 1438-1440
2. Christophers E. Comorbidities in psoriasis. Clin Dermatol 25 (2007) 529-534
3. Feinstein A.R. Clinical judgement revisited: the distraction of quantitative models. Ann Intern Med 120 (1994) 799-805
4. Feinstein A.R. An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med 99 (1983) 843-848
5. Fries J.F. Toward an understanding of patient outcome measurement. Arthritis Rheum 26 (1983) 697-704
6. Last J.M. A dictionary of epidemiology (1988), Oxford University Press, New York
7. Guyatt G.H., Kirshner B., and Jaeschke R. Measuring health status: what are the necessary measurement properties?. J Clin Epidemiol 45 (1992) 1341-1345
8. Farber E.M., and Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica 148 (1974) 1-18
9. Henseler T., Wolff K., Hönigsmann H., and Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1 (1981) 853-857
10. Fredriksson T., and Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
11. Jacobson C.C., and Kimball A.B. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 151 (2004) 381-387
12. Fleischer Jr. A.B., Feldman S.R., and Dekle C.L. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 26 (1999) 210-215
13. Louden B.A., Pearce D.J., Lang W., and Feldman S.R. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J 10 (2004) 7
14. Langley R.G., and Ellis C.N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 51 (2004) 563-569
15. Henseler T., Schmitt-Rau K.A., and comparison between B.S.A. PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 47 (2008) 1019-1023
16. Kirby B., Fortune D.G., Bhushan M., Chalmers R.J., and Griffiths C.E. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 142 (2000) 728-732
17. Feldman S.R. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 15 (2004) 27-29
18. Ashcroft D.M., Wan Po A.L., Williams H.C., and Griffiths C.E. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141 (1999) 185-191
19. Katz S. The science of quality of life. J Chron Dis 40 (1987) 459-463
20. Wilson I.B., and Cleary P.D. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273 (1995) 59-65
21. Finlay A.Y. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 136 (1997) 305-314
22. Gupta M.A., and Gupta A.K. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 75 (1995) 240-243
23. Schmitt J., and Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210 (2005) 194-199
24. European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02. http://www.emea.europa.eu/pdfs/human/ewp/245402en.pdf
25. McHenry P.M., and Doherty V.R. Psoriasis: an audit of patients' views on the disease and its treatment. Br J Dermatol 127 (1992) 13-17
26. Marks R., Barton S.P., Shuttleworth D., and Finlay A.Y. Assessment of disease progress in psoriasis. Arch Dermatol 125 (1989) 235-240
27. Naldi L. Dermatology. In: Day S., Green S.B., and Machin D. (Eds). Textbook of clinical trials (2004), John Wiley & Sons, New York
28. Matthews J.N.S., Altman D.G., Campbell M.J., and Royston P. Analysis of serial measurements in medical research. BMJ 300 (1990) 230-235
29. Brewin C.R., and Bradley C. Patient preferences and randomized trials. Br Med J 299 (1989) 313-315
30. Nijsten T., Looman C.W., and Stern R.S. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 143 (2007) 1113-1121
31. Newell D.J. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 21 (1992) 837-841
32. Kendler K.S. Toward a scientific psychiatric nosology: strengths and limitations. Arch Gen Psychiatry 47 (1990) 969-973
33. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., and Cooper N.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
34. Stucki G., Boonen A., Tugwell P., Cieza A., and Boers M. The World Health Organisation International Classification of Functioning, Disability and Health: a conceptual model and interface for the OMERACT process. J Rheumatol 34 (2007) 600-606